119 results
Page 2 of 6
8-K
EX-99.1
4kote
11 Aug 23
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
6:09am
8-K
943f9
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
EX-99.2
x6kmr2 0v
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
EX-99.1
1dlnr
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
w5kxykywf aj
17 May 23
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
5:01pm
8-K
EX-99.1
0nch09frds vohr1t
17 May 23
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
5:01pm
8-K
EX-1.1
3q5cm
17 May 23
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
5:01pm
8-K
EX-99.1
ix3217dv67fh20 834k
15 May 23
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
7:19am
8-K
EX-99.1
rxei0xr7
29 Mar 23
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
5:20pm
8-K
5yurtdvx75v3ntu1 jb
29 Mar 23
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
5:20pm
8-K
EX-99.1
s0u8jpszl
4 Nov 22
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
7:22am
8-K
EX-1.1
4u6wf11m
16 Sep 22
Entry into a Material Definitive Agreement
4:02pm
8-K
zkfko
16 Sep 22
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-99.2
s9911jv tytkhu43jk
13 Sep 22
Regulation FD Disclosure
9:07am
8-K
EX-99.1
p4iq af023ibuttt2vf
13 Sep 22
Regulation FD Disclosure
9:07am
8-K
u68dj fz3dw
13 Sep 22
Regulation FD Disclosure
9:07am